WO2018197932A1 - Compositions pharmaceutiques de kétorolac - Google Patents

Compositions pharmaceutiques de kétorolac Download PDF

Info

Publication number
WO2018197932A1
WO2018197932A1 PCT/IB2017/054095 IB2017054095W WO2018197932A1 WO 2018197932 A1 WO2018197932 A1 WO 2018197932A1 IB 2017054095 W IB2017054095 W IB 2017054095W WO 2018197932 A1 WO2018197932 A1 WO 2018197932A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
ketorolac
present application
sugar alcohol
insoluble polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2017/054095
Other languages
English (en)
Inventor
Chandrakant Bamtu Velip
Anup Avijit Choudhury
Girish Karanth
Rajeev Singh Raghuvanshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Priority to UAA201911455A priority Critical patent/UA126916C2/uk
Publication of WO2018197932A1 publication Critical patent/WO2018197932A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present application relates to a method of treating pain by providing a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration provides pain relieving concentration in less than about 10 minutes.
  • Ketorolac is a nonsteroidal agent with potent analgesic and moderate antiinflammatory activity. Chemically it is 5-benzoyl-2, 3-dihydro- 1 H-pyrrolizine- 1 - carboxylic acid, the formula of which is:
  • Ketorolac is an inhibitor of prostaglandin synthesis, and has been known for several years by its anti-inflammatory, analgesic and antipyretic action as described in U.S. Pat. No. 4,089,969, in which both the racemic form and each of the dextro and levo isomers of this compound are known.
  • Many pharmaceutically acceptable salts including the most commonly used tromethamine (2-amino-2-hydroxymethyl- 1, 3 -propanediol) salt, are also known.
  • Ketorolac was known to be administered in several routes of administration. For example, U.S. Pat. No.
  • Ketorolac in the form of tromethanol salt is used for oral administration as tablets containing 10 mg strength or oral drops containing 2% solution, by injection provided in flasks containing 10 or 30 mg strengths, and by rectal administration in suppositories form containing 30 mg strength.
  • Ketorolac tromethamine is susceptible to significant degradation in aqueous compositions.
  • the drug is known to undergo chemical degradation via oxidation, hydroxylation and other unknown routes.
  • the oxidative degradation product reported is 1- keto analogue
  • the hydroxylation degradation product reported is 1 -hydroxy analogue.
  • Aqueous and ethanolic solutions of ketorolac or salts thereof are susceptible to degradation when subjected to long term storage under room temperature (PCT application no's. WO 2009/087658 and WO 2012/127497).
  • ketorolac tromethamine is bitter in taste, and adequate degree of palatability is needed especially for a formulation meant for administration through oral cavity.
  • Tablets are most commonly preferred oral dosage forms because of its convenience in terms of self-administration and accurate dosing.
  • problem of this dosage form is poor patient compliance particularly by the geriatric and pediatric patients who experience difficulty in swallowing. Rapidly disintegrating dosage form, particularly one that disintegrates and dissolves/disperses in saliva and can be administered without need of water, is convenient and appreciated.
  • ODT tablets can be prepared by various processes, including, but not limited to Freeze drying (Lyophilization), tablet molding, spray drying, sublimation, direct compression, cotton candy process and mass extrusion.
  • the direct compression represents the simplest and most cost effective tablet manufacturing technique. This technique employs superdisintegrants like croscarmellose sodium, directly compressible diluents, sweeteners and flavoring agents.
  • superdisintegrants like croscarmellose sodium, directly compressible diluents, sweeteners and flavoring agents.
  • not all drugs can be processed as direct compressible formulation either because of their poor flow characteristics or due to their poor compressibility.
  • granulation processes need to be applied to gain compressible blends.
  • the other important factors to be considered in the preparation of an ODT include effective taste- masking and to provide acceptable taste upon oral disintegration.
  • ODT dosage forms can be challenging depending upon drugs and excipients used in the formulations. It is hard to achieve stable ODTs, as most of ingredients used in preparing ODTs dissolve in with minimum quantity of water. Therefore, a careful identification and selection of excipients is critical for the development and long-term stability of the tablets.
  • ketorolac tablets which are available in market are not suitable for acute inflammatory conditions where quick onset of action is required. Particularly due to its use as analgesic, a quick onset of action of ketorolac assumes a significant importance. Multiple attempts were made to provide quick onset of action of ketorolac by formulating it in different possible forms. However, the stability and taste-masking of these formulations appear to be challenging factors, as ketorolac is susceptible to oxidative and hydrolytic degradation, and is bitter in taste leading to poor compliance.
  • Ketorolac Sublingual formulations of Ketorolac are disclosed in US patent no. 7,879,901 wherein a ternary mixture of lactose/sorbitol/cellulose was found to be the essential component of the composition, and the composition is administered sublingually for rapid absorption.
  • PCT application no. WO 2004/108110 discloses a pharmaceutical formulation of a non-steroidal anti-inflammatory agent administered by sublingual route to promote the fast disintegration in the oral cavity, and capable of being absorbed through oral mucosa. Similar to this, US patent no. 7,282,217 and PCT application no. WO 2000/015195 discloses rapidly disintegrating tablet or quick release pharmaceutical compositions.
  • ketorolac there remains a clear unmet clinical need to develop in the art of dosage forms for ketorolac meant for faster pain relief. More specifically there is a need in the art to develop a formulation comprising ketorolac which can be administered orally, that can disintegrate rapidly in the oral cavity, and have improved pharmacokinetic parameters for faster pain relief. It is also desired to have an oral dosage forms with improved taste, and at the same time remains stable thought its shelf life by minimizing hydrolytic and oxidative degradation of the drug.
  • a high rate of absorption of ketorolac in the initial time points is as important as total absorption. It is also important that the initial time point absorption should be as high as possible to achieve minimum effective concentration (MEC) or pain-relieving plasma concentration of the drug.
  • MEC minimum effective concentration
  • Mandema et al, Clin Pharmacol Ther, 1996; 60 (6): 619-35 discloses EC50 of ketorolac tromethamine of 370 ng/mL. It is crucial to achieve a high partial AUC at such minimum effective plasma concentration of the drug. Also, none of the available arts have disclosed a pharmacokinetic profile with high partial AUC at such minimum effective plasma concentration of the drug in less than 10 minutes.
  • the present application relates to a method of treating pain by administering a quick disintegrating composition of ketorolac, wherein said composition upon oral administration provides pain relieving concentration in less than about 10 minutes.
  • a composition of ketorolac that disintegrates or disperses in the oral cavity in less than about 30 seconds.
  • oral dosage form that eases the swallowing of the dosage forms.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration provides a pain relieving concentration in less than about 10 minutes.
  • the composition of the present application upon oral administration provides a pain relieving concentration of at least about 370 ng/ml in less than about 10 minutes.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration provides a pain relieving concentration of at least about 370 ng/ml in less than about 10 minutes.
  • the composition of the present application comprises ketorolac in an amount of about 5 mg to about 10 mg.
  • composition of the present application comprises ketorolac in an amount of about 5 mg.
  • composition of the present application comprises ketorolac in an amount of about 10 mg.
  • composition of the present application comprises at least one water insoluble polymer.
  • composition of the present application comprises at least one sugar alcohol.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising:
  • ketorolac or a pharmaceutically acceptable salt thereof
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising:
  • ketorolac or a pharmaceutically acceptable salt thereof
  • composition upon oral administration provides a pain relieving concentration in less than about 10 minutes.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising:
  • ketorolac or a pharmaceutically acceptable salt thereof
  • composition upon oral administration provides a pain relieving concentration of at least about 370 ng/ml in less than about 10 minutes.
  • composition of the present application upon oral administration exhibits a Ti ag of less than about 5 minutes.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising:
  • ketorolac or a pharmaceutically acceptable salt thereof
  • composition upon oral administration exhibits a Ti ag of less than about 5 minutes.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising:
  • ketorolac or a pharmaceutically acceptable salt thereof, (b) at least one water insoluble polymer, and
  • composition upon oral administration exhibits a Ti ag of less than about 5 minutes and provides a pain relieving concentration of at least about 370 ng/ml in less than about 10 minutes.
  • composition of the present application upon oral administration exhibits at least one of the following pharmacokinetic parameters:
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration exhibits higher partial AUCs compared to the commercially available ketorolac composition.
  • the composition of the present application upon oral administration exhibits AUCo-Smin of about 4.5 fold higher compared to commercially available ketorolac composition.
  • the composition of the present application upon oral administration exhibits AUCo-iOmin of about 2.6 fold higher compared to commercially available ketorolac composition.
  • the composition of the present application upon oral administration exhibits AUCo-20min of about 1.5 fold higher compared to commercially available ketorolac composition.
  • the composition of the present application upon oral administration exhibits AUCo-30min of about 1.3 fold higher compared to commercially available ketorolac composition.
  • the composition of the present application upon oral administration exhibits bioequivalence to a commercially available ketorolac composition when administered to the human subjects in fasting condition, wherein said bioequivalence is established by: (a) a 90% Confidence Interval for mean C m ax, which is between 80% and 125%, (b) a 90% Confidence Interval for mean AUC(o-t), which is between 80% and 125% and (c) a 90% Confidence Interval for mean AUC(o- ⁇ >, which is between 80% and 125%.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • the composition of the present application comprises ketorolac in an amount of about 5 mg to about 10 mg.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • composition comprises ketorolac in an amount of about 5 mg to about 10 mg.
  • composition of the present application disintegrates in less than about 30 seconds when placed in the oral cavity.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • composition disintegrates in less than about 30 seconds when placed in the oral cavity.
  • composition of the present application exhibits at least one of the following in- vitro release profile:
  • ketorolac i. releases at least about 80% of ketorolac within about 5 minutes when measured in 600ml of pH 1.2 simulated gastric fluid at 50 rpm and at 37°C using USP type II apparatus; ii. releases at least about 90% of ketorolac within about 5 minutes when measured in 600ml of pH 4.5 acetate buffer at 50 rpm and at 37°C using USP type II apparatus; or
  • ketorolac releases at least about 95% of ketorolac within about 5 minutes when measured in 600ml of pH 6.8 phosphate buffer and/or purified water at 50 rpm and at 37°C using USP type II apparatus.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • composition exhibits at least one of the following in-vitro release profile:
  • ketorolac Owithin i. releases at least about 80% of ketorolac Owithin about 5 minutes when measured in 600ml of pH 1.2 simulated gastric fluid at 50 rpm and at 37°C using USP type II apparatus;
  • ketorolac releases at least about 90% of ketorolac within about 5 minutes when measured in 600ml of pH 4.5 acetate buffer at 50 rpm and at 37°C using USP type II apparatus;
  • ketorolac releases at least about 95% of ketorolac within about 5 minutes when measured in 600ml of pH 6.8 phosphate buffer and/or purified water at 50 rpm and at 37°C using USP type II apparatus.
  • the composition of the present application comprises water insoluble polymer and sugar alcohol in a weight ratio of from about 1.0: 1.0 to about 1.5: 1.0.
  • the composition of the present application comprises ketorolac and sugar alcohol in a weight ratio of from about 0.3: 1.0 to about 1.0: 1.0.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • composition comprises water insoluble polymer and sugar alcohol in a weight ratio of from about 1.0: 1.0 to about 1.5: 1.0.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • composition comprises ketorolac and sugar alcohol in a weight ratio of from about 0.3: 1.0 to about 1.0: 1.0.
  • the composition of the present application comprises water insoluble polymer in an amount of from about 30% to about 60% by weight of the composition.
  • the composition of the present application comprises said sugar alcohol is present in an amount of from about 20% to about 50% by weight of the composition.
  • composition of the present application further comprises a stabilizer selected from water-insoluble antioxidants, pH modifiers or mixtures thereof.
  • the composition of the present application is stable for at least about 3 months upon storage at 25 °C / 60% relative humidity (RH) and produces less than 0.5% of total impurities.
  • the composition of the present application is stable for at least about 3 months upon storage at 40°C / 75% relative humidity (RH) and produces less than 0.5% of total impurities.
  • the composition of the present application is stable for at least about 6 months upon storage at 25 °C / 60% relative humidity (RH) and produces less than 1.0% of total impurities.
  • the composition of the present application is stable for at least about 6 months upon storage at 40°C / 75% relative humidity (RH) and produces less than 1.0% of total impurities.
  • the composition of the present application is formulated in form of tablets, lozenges, caplets, pills, wafers, films, powders, granules or sachets.
  • FIG. 1 shows plasma ketorolac concentration (ng/mL) vs. time (hr) for an exemplary composition of the present application, as set forth in Example 1 containing lOmg of ketorolac, vis-a-vis KETOROL ® lOmg oral tablets administered to healthy human subjects in fasting condition.
  • the term "at least” refers to presence of recited substance in the composition in recited least amount.
  • composition As used herein, the terms “pharmaceutical composition”, “composition” and “formulation” are used interchangeably and refer to a mixture of two or more compounds, elements, or molecules. Also the terms “composition” and “formulation” may be used to refer to a mixture of one or more active agents with excipients or other carriers, and include solid pharmaceutical products such as tablets, capsules, sachets, pills, or granules, containing a mixture of two or more compounds, elements or molecules.
  • the term "quick disintegrating composition” can include one or more composition(s) or formulation(s) provided in an acceptable form for oral administration, wherein said composition which upon administration or when placed inside the oral cavity of the subject or patient, disintegrates or disperses or dissolves within about 60 seconds or less, or within about 30 seconds or less, or within about 15 seconds or less and eases the dosage administration. It also refers to composition that disintegrates or disperses rapidly when contacted with a fluid, particularly an aqueous fluid (e.g., water, bodily fluids (e.g., saliva), and the like), which can be easily swallowed.
  • the quick disintegrating composition of the present application can be present in the form of tablets, lozenges, caplets, pills, wafers, films, powders, granules or sachets.
  • disintegrate is well -understood in the art, and while a composition can be completely disintegrated, the term disintegrate does not necessarily refer to a complete dissolution of the composition, although a dissolved composition (e.g., tablet, lozenge, etc.) would typically be completely disintegrated.
  • terapéuticaally effective amount refers to a non-toxic, but sufficient amount of the drug, to achieve therapeutic results in treating a condition for which the drug is known to be effective.
  • an effective amount is an amount of ketorolac that is approximately from about 5 mg to about 10 mg, which is sufficient to provide patients some measure of analgesia or helps in the management of acute, severe or moderate pain or its associated conditions, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment.
  • the effective amount of said ketorolac or a pharmaceutically acceptable salt will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, and like factors within the knowledge and expertise of the attending physician.
  • excipients refers to any pharmaceutically acceptable materials or components of a pharmaceutical product suitable for the present pharmaceutical preparation and as disclosed herein, that is not having any pharmacological effect, such as a filler, diluent, carrier, etc.
  • the excipients that are useful in preparing a pharmaceutical composition are generally safe, nontoxic, do not interact with other components of a composition in a deleterious manner, and are acceptable for veterinary or human use.
  • An “excipient” or a “pharmaceutically acceptable excipient” as used in the specification includes both one and more than one such excipients.
  • ketolac refers to its free base, pharmaceutically acceptable salts, acid addition salts, all polymorphic forms (amorphous or crystalline), hydrates, anhydrous forms, enantiomers, prodrugs of ketorolac and/or mixtures thereof.
  • ketorolac refers to ketorolac tromethamine.
  • pharmaceutically acceptable salt includes derivatives of the disclosed compounds which are, within the scope of sound medical judgment, suitable for use in humans and lower animals without undue toxicity, irritation, allergic response and the like, which are well known in the art.
  • the salt can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by the reaction of the pharmaceutically active substance, having a freebase function, with a suitable organic acid or inorganic acid. Further refers to pharmaceutically acceptable solvates, including hydrates, of such compounds and such salt.
  • RH 60% relative humidity
  • RH 40°C / 75% relative humidity
  • pain refers to pain as recited herein acute pain, migraine pain, cluster headache, neuropathic pain, post-operative pain, chronic lower back pain, herpes neuralgia, phantom limb pain, central pain, dental pain, neuropathic pain, opioid- resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting from burns, including sunburn, post-partum pain, angina pain, and genitourinary tract-related pain including cystitis, arthritis pain, inflammation, osteoarthritis, juvenile rheumatoid arthritis, ankylosing spondylitis and primary dysmenorrhea.
  • treating pain refers to the short-term ( ⁇ 5 days) management of moderately severe acute pain that requires analgesia effect, usually in a postoperative patient.
  • Cp plasma concentrations
  • partial AUC refers to the area under the plasma concentration versus time profile over a specified time period, which represents the drug exposure for any time interval of interest, and is calculated by the log-linear trapezoidal rule over the partial dosing interval.
  • AUC refers to the area under the plasma concentration versus time profile, as calculated by the log-linear trapezoidal rule over the complete dosing interval.
  • C m ax refers to the highest plasma concentration of the drug attained within the dosing interval.
  • T m ax refers to the time period which elapses after administration of a single dosage form at which the plasma concentration of the drug attains the highest plasma concentration of drug attained within the dosing interval.
  • Ti ag refers to time delay between administration of the composition and first observed drug concentration in plasma, which is within a limit of quantification.
  • ketorolac composition refers to KETOROL ® oral tablets containing lOmg ketorolac tromethamine or its pharmaceutical equivalents or its therapeutic equivalents or later approved drugs.
  • KETOROL ® includes compressed tablet of ketorolac tromethamine equivalent to 5 mg or 10 mg of ketorolac base along with excipients.
  • KETOROL ® includes its approved therapeutic or pharmaceutical equivalents.
  • KETOROL ® is marketed by Dr. Reddy's Laboratories, Ltd., Russia.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration provides a pain relieving concentration in less than about 10 minutes.
  • the composition of the present application upon oral administration provides a pain relieving concentration of at least about 370 ng/ml in less than about 10 minutes.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration provides a pain relieving concentration of at least about 370 ng/ml in less than about 10 minutes.
  • the composition of the present application comprises ketorolac in an amount of about 5 mg to about 10 mg.
  • composition of the present application comprises ketorolac in an amount of about 5 mg.
  • composition of the present application comprises ketorolac in an amount of about 10 mg.
  • the present composition of the present application upon oral administration to a human subject under fasting conditions provides Ti ag of less than about 5 minutes, or less than about 4 minutes, or less than about 3 minutes, or less than about 2 minutes, or less than about 1 minute.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration exhibits a Ti ag of less than about 5 minutes.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration exhibits a Ti ag of less than about 5 minutes and provides a pain relieving concentration in less than about 10 minutes.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration exhibits a Ti ag of less than about 5 minutes and provides a pain relieving concentration of at least about 370 ng/ml in less than about 10 minutes.
  • composition of the present application comprises at least one water insoluble polymer.
  • composition of the present application comprises at least one sugar alcohol.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising:
  • ketorolac or a pharmaceutically acceptable salt thereof
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising:
  • ketorolac or a pharmaceutically acceptable salt thereof
  • composition upon oral administration provides a pain relieving concentration in less than about 10 minutes.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising:
  • ketorolac or a pharmaceutically acceptable salt thereof
  • composition upon oral administration provides a pain relieving concentration of at least about 370 ng/ml in less than about 10 minutes.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising:
  • ketorolac or a pharmaceutically acceptable salt thereof
  • composition upon oral administration exhibits a Ti ag of less than about 5 minutes.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising:
  • ketorolac or a pharmaceutically acceptable salt thereof
  • composition upon oral administration exhibits a Ti ag of less than about 5 minutes and provides a pain relieving concentration in less than about 10 minutes.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising: (a) therapeutically effective amount of ketorolac or a pharmaceutically acceptable salt thereof,
  • composition upon oral administration exhibits a Ti ag of less than about 5 minutes and provides a pain relieving concentration of at least about 370 ng/ml in less than about 10 minutes.
  • the quick disintegrating composition of ketorolac discloses herein can have variety of improved pharmacokinetic parameters.
  • the composition of the present application can have an improved pharmacokinetic parameter in comparison to a commercially available ketorolac oral composition, such as AUCo-5min, AUCo-iOmin, AUCo-
  • composition of the present application upon oral administration exhibits at least one of the following pharmacokinetic parameters:
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration exhibits AUCo-Smin from about 2.64 ng.hr/ml to about 3.96 ng.hr/ml.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration exhibits AUCo-Smin of about 4.5 fold higher compared to commercially available ketorolac composition.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration exhibits AUCo-iOmin from about 23.35 ng.hr/ml to about 35.03 ng.hr/ml.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration exhibits AUCo-iOmin of about 2.6 fold higher compared to commercially available ketorolac composition.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration exhibits AUCo-20min from about 128.20 ng.hr/ml to about 192.30 ng.hr/ml.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration exhibits AUCo-20min of about 1.5 fold higher compared to commercially available ketorolac composition.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration exhibits AUCo-30min from about 297.99 ng.hr/ml to about 446.99 ng.hr/ml.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition upon oral administration exhibits AUCo-30min of about 1.3 fold higher compared to commercially available ketorolac composition.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising:
  • ketorolac or a pharmaceutically acceptable salt thereof
  • composition upon oral administration exhibits at least one of the following pharmacokinetic parameters: (a) AUCo-5min from about 2.64 ng.hr/ml to about 3.96 ng.hr/ml;
  • the composition of the present application upon oral administration exhibits bioequivalence to a commercially available ketorolac composition when administered to the human subjects in fasting condition.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition when administered to said patient under fasting condition exhibits bioequivalence to a commercially available ketorolac composition.
  • the composition of the present application upon oral administration exhibits bioequivalence to a commercially available ketorolac composition when administered to the human subjects in fasting condition, wherein said bioequivalence is established by: (a) a 90% Confidence Interval for mean C m ax, which is between 80% and 125%, (b) a 90% Confidence Interval for mean AUC(o-t), which is between 80% and 125% and (c) a 90% Confidence Interval for mean AUC(o- ⁇ >, which is between 80% and 125%.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising:
  • ketorolac or a pharmaceutically acceptable salt thereof
  • composition exhibits bioequivalence to a commercially available ketorolac composition when administered to the human subjects in fasting condition.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising:
  • ketorolac or a pharmaceutically acceptable salt thereof, (b) at least one water insoluble polymer, and
  • composition exhibits bioequivalence to a commercially available ketorolac composition when administered to the human subjects in fasting condition and said bioequivalence is established by: (a) a 90% Confidence Interval for mean C m ax, which is between 80% and 125%, (b) a 90% Confidence Interval for mean AUQo-t), which is between 80% and 125% and (c) a 90% Confidence Interval for mean AUC(o- ⁇ >, which is between 80% and 125%.
  • the composition of the present application comprises ketorolac in an amount of about 5 mg to about 10 mg.
  • composition of the present application comprises ketorolac in an amount of about 5 mg.
  • composition of the present application comprises ketorolac in an amount of about 10 mg.
  • the present method of treating pain in a patient in need thereof comprises administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition disintegrates in less than about 30 seconds when placed in the oral cavity.
  • the present method of treating pain in a patient in need thereof comprises administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition disintegrates in less than about 15 seconds, about 20 seconds, about 25 seconds or about 30 seconds when placed in the oral cavity.
  • the present application relates to a method of treating pain in a patient in need thereof comprising administering to the patient a quick disintegrating composition of ketorolac comprising:
  • ketorolac or a pharmaceutically acceptable salt thereof
  • composition disintegrates in less than about 30 seconds when placed in the oral cavity.
  • the present method of treating pain in a patient in need thereof comprises administering to the patient a quick disintegrating composition of ketorolac or a pharmaceutically acceptable salt thereof, wherein said composition is in the form of tablets, lozenges, caplets, pills, wafers, films, powders, granules or sachets.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • composition comprises ketorolac in an amount of about 5 mg to about 10 mg.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • ketorolac in an amount of about 5 mg.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • composition comprises ketorolac in an amount of about 10 mg.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • composition disintegrates in less than about 30 seconds when placed in the oral cavity.
  • the composition of the present application comprises water insoluble polymer and sugar alcohol in a weight ratio of from about 1.0: 1.0 to about 1.5: 1.0.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • water insoluble polymer and said sugar alcohol are present in a weight ratio of from about 1.0: 1.0 to about 1.5: 1.0.
  • the composition of the present application comprises ketorolac and sugar alcohol in a weight ratio of from about 0.3: 1.0 to about 1.0: 1.0.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising: (a) an intragranular portion comprising therapeutically effective amount of ketorolac or a pharmaceutically acceptable salt thereof and at least one water insoluble polymer,
  • ketorolac and said sugar alcohol are present in a weight ratio of from about 0.3: 1.0 to about 1.0: 1.0.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • composition releases at least about 80% of ketorolac within about 5 minutes when measured in 600ml of pH 1.2 simulated gastric fluid at 50 rpm and at 37°C using USP type II apparatus.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • composition releases at least about 90% of ketorolac within about 5 minutes when measured in 600ml of pH 4.5 acetate buffer at 50 rpm and at 37°C using USP type II apparatus.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • composition releases at least about 95% of ketorolac within about 5 minutes when measured in 600ml of pH 6.8 phosphate buffer and/or purified water at 50 rpm and at 37°C using USP type II apparatus.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • composition exhibits at least one of the following in-vitro release profile:
  • ketorolac i. releases at least about 80% of ketorolac within about 5 minutes when measured in 600ml of pH 1.2 simulated gastric fluid at 50 rpm and at 37°C using USP type II apparatus;
  • ketorolac releases at least about 90% of ketorolac within about 5 minutes when measured in 600ml of pH 4.5 acetate buffer at 50 rpm and at 37°C using USP type II apparatus;
  • ketorolac releases at least about 95% of ketorolac within about 5 minutes when measured in 600ml of pH 6.8 phosphate buffer and/or purified water at 50 rpm and at 37°C using USP type II apparatus.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • said water insoluble polymer and said sugar alcohol are present in a weight ratio of from about 1.0: 1.0 to about 1.5: 1.0 and said composition exhibits at least one of the following in-vitro release profile: i. releases at least about 80% of ketorolac within about 5 minutes when measured in 600ml of pH 1.2 simulated gastric fluid at 50 rpm and at 37°C using USP type II apparatus;
  • ketorolac releases at least about 90% of ketorolac within about 5 minutes when measured in 600ml of pH 4.5 acetate buffer at 50 rpm and at 37°C using USP type II apparatus;
  • ketorolac releases at least about 95% of ketorolac within about 5 minutes when measured in 600ml of pH 6.8 phosphate buffer and/or purified water at 50 rpm and at 37°C using USP type II apparatus.
  • the present application relates to a quick disintegrating oral composition of ketorolac comprising:
  • ketorolac and said sugar alcohol are present in a weight ratio of from about 0.3: 1.0 to about 1.0: 1.0 and said composition exhibits at least one of the following in-vitro release profile:
  • ketorolac i. releases at least about 80% of ketorolac within about 5 minutes when measured in 600ml of pH 1.2 simulated gastric fluid at 50 rpm and at 37°C using USP type II apparatus;
  • ketorolac releases at least about 90% of ketorolac within about 5 minutes when measured in 600ml of pH 4.5 acetate buffer at 50 rpm and at 37°C using USP type II apparatus;
  • ketorolac releases at least about 95% of ketorolac within about 5 minutes when measured in 600ml of pH 6.8 phosphate buffer and/or purified water at 50 rpm and at 37°C using USP type II apparatus.
  • the quick disintegrating oral composition of the present application comprises at least one water insoluble polymer in the intra-granular portion.
  • the water insoluble polymer may be present in the composition disclosed herein a variety of concentrations.
  • the quick disintegrating oral composition disclosed herein can comprise water insoluble polymer in an amount of at least 30% by weight, at least 35% by weight, at least 40% by weight, at least 45% by weight, at least 50% by weight, at least 55% by weight, at least 60% by weight, or a percentage between any two of the above values, based on the total weight of the composition.
  • the quick disintegrating oral composition of ketorolac of present application comprises of at least one water insoluble polymer in an amount of from about 30% to about 60% by weight, or from about 30% to about 55% by weight, or from about 30% to about 50% by weight, or from about 30% to about 45% by weight, or from about 30% to about 40% by weight, or from about 30% to about 35% by weight, based on the total weight of the composition.
  • Suitable examples of water insoluble polymer used in the present application include, but are not limited to, microcrystalline cellulose, ethyl cellulose, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, cross-linked dextran and the like or mixtures thereof.
  • the quick disintegrating oral composition of the present application comprises at least one sugar alcohol in the extra-granular portion.
  • Sugar alcohol present in extra-granular portion helps in avoiding the problem of sticking during the granulation process and also helps to achieve desired disintegration/ dissolution of the formulation in the oral cavity.
  • the sugar alcohol may be present in the composition disclosed herein a variety of concentrations.
  • the quick disintegrating oral composition disclosed herein can comprise sugar alcohol at least 20% by weight, at least 25% by weight, at least 30% by weight, at least 35% by weight, at least 40% by weight, at least 45% by weight, at least 50% by weight, or a percentage between any two of the above values, based on the total weight of the composition.
  • the quick disintegrating oral composition of ketorolac of present application comprises of at least one sugar alcohol in an amount of from about 20% to about 50% by weight, or from about 20% to about 45% by weight, or from about 20% to about 40% by weight, or from about 20% to about 35% by weight, or from about 20% to about 30% by weight, or from about 20% to about 25% by weight, based on the total weight of the composition.
  • Suitable examples of sugar alcohol used in the present application include, but are not limited to, mannitol, maltitol, sorbitol, xylitol, lactitol, erythritol, isomalt, threitol and the like or mixtures thereof.
  • the quick disintegrating oral composition of ketorolac of present application comprises at least one stabilizer selected from selected from water- insoluble antioxidants, pH modifiers or mixtures thereof.
  • the stabilizer may be present in the composition disclosed herein a variety of concentrations.
  • the quick disintegrating oral composition disclosed herein can comprise stabilizer at least 0.05% by weight, at least 0.06% by weight, at least 0.07% by weight, at least 0.08% by weight, at least 0.09% by weight, at least 0.1% by weight, or a percentage between any two of the above values, based on the total weight of the composition.
  • the amount of stabilizer that may be used in the present application ranges from about 0.05% to about 1.0% by weight of the composition.
  • Suitable examples of water-insoluble antioxidants used as a stabilizer in the present application include, but are not limited to, butylated hydroxyanisole (BHA), butylated hydroxy toluene (BHT) or mixtures thereof.
  • pH modifiers used as a stabilizer in the present application include, but are not limited to, citric acid, tartaric acid, maleic acid, fumaric acid, succinic acid, maleic acid, meglumine, sodium hydroxide, potassium hydroxide, sodium bicarbonate, buffering agents such as phosphate buffer, acetate buffer, borate buffer or mixtures thereof.
  • the pharmaceutical composition of the present application further comprises pharmaceutically-acceptable excipients selected from the group of diluents, lubricants, glidants, sweeteners, solvent such as non-aqueous solvent includes, but not limited to, various organic solvents, for example, lower alcohols such as methanol and ethanol, isopropyl alcohol, ketones such as acetone and methyl ethyl ketone, methylene chloride, and the like.
  • solvent such as non-aqueous solvent includes, but not limited to, various organic solvents, for example, lower alcohols such as methanol and ethanol, isopropyl alcohol, ketones such as acetone and methyl ethyl ketone, methylene chloride, and the like.
  • Suitable pharmaceutically-acceptable excipients that may be used to formulate the present the quick disintegrating oral composition, are any excipients known to a person skilled in the art, and are described in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (1986), incorporated herein by reference.
  • the pharmaceutical composition of the present application is stable for at least about 3 months upon storage at 25 °C / 60% relative humidity (RH).
  • the pharmaceutical composition of the present application is stable for at least about 3 months upon storage at 40°C / 75% relative humidity (RH).
  • the quick disintegrating oral composition of the present application is stable for at least about 3 months upon storage at 25 °C / 60% relative humidity (RH). [00153] In another embodiment, the quick disintegrating oral composition of the present application is stable for at least about 3 months upon storage at 40°C / 75% relative humidity (RH).
  • the quick disintegrating oral composition of the present application is stable for at least about 6 months upon storage at 25 °C / 60% relative humidity (RH).
  • the quick disintegrating oral composition of the present application is stable for at least about 6 months upon storage at 40°C / 75% relative humidity (RH).
  • the quick disintegrating oral composition of the present application is stable for at least about 3 months upon storage at 25 °C / 60% relative humidity (RH) and produces less than 0.5% of total impurities.
  • the quick disintegrating oral composition of the present application is stable for at least about 3 months upon storage at 40°C / 75% relative humidity (RH) and produces less than 0.5% of total impurities.
  • the quick disintegrating oral composition of the present application is stable for at least about 6 months upon storage at 25 °C / 60% relative humidity (RH) and produces less than 1.0% of total impurities.
  • the quick disintegrating oral composition of the present application is stable for at least about 6 months upon storage at 40°C / 75% relative humidity (RH) and produces less than 1.0% of total impurities.
  • the quick disintegrating oral composition of the present application comprising:
  • composition is stable for at least about 3 months upon storage at 25 °C / 60% relative humidity (RH).
  • the quick disintegrating oral composition of the present application comprising:
  • composition is stable for at least about 3 months upon storage at 40°C / 75% relative humidity (RH).
  • the quick disintegrating oral composition of the present application comprising:
  • composition is stable for at least about 3 months upon storage at 25°C / 60% relative humidity (RH) and produces less than 0.5% of total impurities.
  • the quick disintegrating oral composition of the present application comprising:
  • composition is stable for at least about 3 months upon storage at 40°C / 75% relative humidity (RH) and produces less than 0.5% of total impurities.
  • the quick disintegrating oral composition of the present application comprising:
  • composition is stable for at least about 6 months upon storage at 25°C / 60% relative humidity (RH) and produces less than 1.0% of total impurities.
  • the quick disintegrating oral composition of the present application comprising: (a) an intragranular portion comprising therapeutically effective amount of ketorolac or a pharmaceutically acceptable salt thereof and at least one water insoluble polymer, and
  • composition is stable for at least about 6 months upon storage at 40°C / 75% relative humidity (RH) and produces less than 1.0% of total impurities.
  • the quick disintegrating oral composition of the present application can be packaged in any suitable packaging material known in the art that can ensure the stability of said composition and ketorolac or a pharmaceutically-acceptable salt thereof during storage, transit and administration.
  • the quick disintegrating oral composition of the present application can be packaged using suitable packaging materials selected from high-density polyethylene (HDPE) container, aluminum-aluminum (Alu-Alu) blister package, aluminum-desiccant-aluminum (Alu-Des-Alu) blister package or polyvinyl chloride - polyvinylidene chloride (PVC-PVdC) blister package and the like materials.
  • suitable packaging materials selected from high-density polyethylene (HDPE) container, aluminum-aluminum (Alu-Alu) blister package, aluminum-desiccant-aluminum (Alu-Des-Alu) blister package or polyvinyl chloride - polyvinylidene chloride (PVC-PVdC) blister package and the like materials.
  • HDPE high-density polyethylene
  • Alu-Alu aluminum-aluminum
  • Alu-Des-Alu aluminum-desiccant-aluminum
  • the quick disintegrating oral composition of the present application comprising:
  • composition is packaged using aluminum-desiccant-aluminum (Alu-Des-Alu) blister package, and said composition is stable for at least about 3 months upon storage at 25 °C / 60% relative humidity (RH) and produces less than 0.5% of total impurities.
  • Alu-Des-Alu aluminum-desiccant-aluminum
  • the quick disintegrating oral composition of the present application comprising:
  • composition is packaged using aluminum-desiccant-aluminum (Alu-Des-Alu) blister package, and said composition is stable for at least about 3 months upon storage at 40°C / 75% relative humidity (RH) and produces less than 0.5% of total impurities.
  • Alu-Des-Alu aluminum-desiccant-aluminum
  • the quick disintegrating oral composition of the present application comprising:
  • ketorolac an intragranular portion comprising therapeutically effective amount of ketorolac or a pharmaceutically acceptable salt thereof and at least one water insoluble polymer
  • composition is packaged using aluminum-desiccant-aluminum (Alu-Des-Alu) blister package, and said composition is stable for at least about 6 months upon storage at 25 °C / 60% relative humidity (RH) and produces less than 1.0% of total impurities.
  • Alu-Des-Alu aluminum-desiccant-aluminum
  • the quick disintegrating oral composition of the present application comprising:
  • composition is packaged using aluminum-desiccant-aluminum (Alu-Des-Alu) blister package, and said composition is stable for at least about 6 months upon storage at 40°C / 75% relative humidity (RH) and produces less than 1.0% of total impurities.
  • Alu-Des-Alu aluminum-desiccant-aluminum
  • the present application relates to a process to prepare a quick disintegrating oral composition comprising ketorolac or a pharmaceutically acceptable salt thereof, which includes any method known to a person skilled in the art such as, but not limited to, spraying a suspension or dispersion of drug in a conventional coating pan or fluidized bed equipment (such as a Wurster or Glatt) to prepare drug containing granules, followed by drying of the granules when desired granule size is achieved.
  • a conventional coating pan or fluidized bed equipment such as a Wurster or Glatt
  • Such prepared drug containing granules can be mixed with extragranular material including sugar alcohol to prepare desired pharmaceutical composition.
  • any method known to a person skilled in the art such as, but not limited to, operations such as mixing, granulation methods employing planetary mixer, a screw mixer and the like; high-speed mixing granulation methods using a Henschel mixer, a Super mixer and the like; extruding granulation methods using a cylindrical granulator, a rotary granulator, a screw extruding granulator, a pellet mill type granulator and the like; wet high-shear granulation methods, fluidized-bed granulation methods, compression granulation methods, crushing granulation methods and spraying granulation methods can be used.
  • drying operation can be performed using an oven dryer, a fluidized bed dryer and the like; post drying crushing and sieving can be carried out to obtain granules or fine granules for use.
  • Suitable equipment for processing pharmaceutical compositions of the present application include, but not limited to, mechanical sifters, blenders, roller compactors, granulators (rapid mixer or fluid bed granulator), fluid bed dryers, compression machines, rotating bowls or coating pans or a combinations of various equipment.
  • the present application relates to a process to prepare quick disintegrating oral composition of ketorolac comprises the steps of:
  • step (b) granulating the mixture of step (a) with required quantity of stabilizer
  • step (c) drying the granules of step (b) followed by mixing with extra-granular material comprising at least one sugar alcohol;
  • step (d) formulating the mixture of step (c) into desired composition.
  • the present application relates to a process to prepare quick disintegrating oral composition of ketorolac comprises the steps of:
  • step (b) granulating the mixture of step (a) with required quantity of stabilizer
  • step (c) drying the granules of step (b) followed by mixing with extra-granular material comprising at least one sugar alcohol;
  • water insoluble polymer and sugar alcohol are present in a weight ratio of from about 1.0: 1.0 to about 1.5: 1.0.
  • the present application relates to a process to prepare quick disintegrating oral composition of ketorolac comprises the steps of: (a) preparing a mixture of therapeutically effective amount of ketorolac and at least one water insoluble polymer;
  • step (b) granulating the mixture of step (a) with required quantity of stabilizer
  • step (c) drying the granules of step (b) followed by mixing with extra-granular material comprising at least one sugar alcohol;
  • ketorolac and sugar alcohol are present in a weight ratio of from about 0.3: 1.0 to about 1.0: 1.0.
  • the process of preparing quick disintegrating composition of ketorolac comprises applying/ spraying the stabilizer over the granules using at least one non-aqueous solvent.
  • the present quick disintegrating composition of ketorolac can be formulated in form of tablets, lozenges, caplets, pills, wafers, films, powders, granules or sachets.
  • the quick disintegrating oral composition of ketorolac is formulated as taste-masked composition, to mask the bitter taste of ketorolac, and to have an improved taste, palatability and patient compliance.
  • the quick disintegrating oral composition of ketorolac can be administered with or without a sip of water.
  • the present quick disintegrating oral composition of ketorolac can also be co-administered (simultaneously or sequentially) with one or more pharmaceutical agents of value in treating pain or related disease conditions.
  • the quick disintegrating oral composition of ketorolac can be administered for the treatment of acute pain including short-term ( ⁇ 5 days), management of moderately to severe acute pain that requires analgesia at the opioid level, or as advised by the qualified physician.
  • ketorolac or a pharmaceutically acceptable salt thereof may be prepared as given in Table 1.
  • Ketorolac tromethamine and other intragranular materials were mixed and granulated using purified water.
  • step (b) The granules obtained in step (a) were dried.
  • step (d) The granules obtained in step (c) were dried, sifted and milled till desired size is obtained.
  • Example 4 [00190] The pharmacokinetic parameters for quick disintegrating oral composition as prepared in Example 1 containing ketorolac lOmg was studied in comparison with KETOROL ® 10 mg oral tablets. A randomized, open-label, single dose, two-treatment, two- period, two-sequence, crossover, comparative bioavailability study was done by administering a single dose oral composition of Example 1 (containing ketorolac lOmg) and KETOROL ® 10 mg oral tablets (Dr. Reddy's Laboratories Ltd, Russia) in 18 healthy, adult, male subjects under fasting conditions. The results of various pharmacokinetic data are shown in Tables 2, 3, 4 and in Figure 1.
  • exemplary composition of the present application as set forth in Example 1 containing lOmg of ketorolac achieves minimum effective concentration (MEC) or pain relieving concentration of about 370 ng/mL, in about 8.5 minutes (0.14 hr) compared to 12 minutes (0.20 hr) of KETOROL ® lOmg oral tablets.
  • Example 1 The pharmaceutical compositions as prepared in Example 1, 2 and 3 were subjected for disintegration study in comparison with KETOROL ® (10 mg). The results are shown in Table 5.
  • Example 1 The pharmaceutical composition as prepared in Example 1 was subjected to dissolution studies in different media like, purified water, pH 1.2 simulated gastric juice, pH 4.5 acetate buffer and pH 6.8 phosphate buffer. The study was conducted using 600ml media, at 50 rpm, at 37°C using USP type II apparatus. The dissolution results in comparison with KETOROL ® (10 mg) are shown in Table 7.
  • Example 1 The pharmaceutical composition as prepared in Example 1 was studied for effect of different packaging materials. Composition of Example 1 was packed in using Alu- Alu Blister and Alu-Des-Alu Blister as packaging materials and the packaged compositions were subjected to accelerated stability testing for a period of 6 months under storage conditions at 40°C /75% RH. At the end of 6 months, the compositions were tested for various parameters and the results are shown in Table 8.
  • Alu-Alu Aluminum-Aluminum
  • Alu-Des-Alu Aluminum-Desiccant-Aluminum
  • Example 1 and 2 The pharmaceutical compositions as prepared in Example 1 and 2 containing different antioxidant concentration were studied for its effect during stability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une méthode de traitement de la douleur par fourniture d'une composition à désintégration rapide de kétorolac, ladite composition offrant lors de son administration une concentration de soulagement de la douleur en moins 10 minutes environ.
PCT/IB2017/054095 2017-04-27 2017-07-07 Compositions pharmaceutiques de kétorolac Ceased WO2018197932A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAA201911455A UA126916C2 (uk) 2017-04-27 2017-07-07 Фармацевтична композиція кеторолаку

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741014984 2017-04-27
IN201741014984 2017-04-27

Publications (1)

Publication Number Publication Date
WO2018197932A1 true WO2018197932A1 (fr) 2018-11-01

Family

ID=59677261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/054095 Ceased WO2018197932A1 (fr) 2017-04-27 2017-07-07 Compositions pharmaceutiques de kétorolac

Country Status (3)

Country Link
RU (1) RU2677663C1 (fr)
UA (1) UA126916C2 (fr)
WO (1) WO2018197932A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024211978A1 (fr) * 2023-04-13 2024-10-17 Aché Laboratórios Farmacêuticos S.A. Composition pharmaceutique orale, procédé de production de granulés ou d'une composition pharmaceutique orale, granulé pharmaceutique oral, utilisation de la composition pharmaceutique et méthode de traitement d'états inflammatoires, de la douleur et/ou pour éviter l'utilisation d'opioïdes en péri-opératoire

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210228677A1 (en) * 2020-01-28 2021-07-29 Pharmbiotech OY Pharmaceutical composition and a method for its manufacture

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
WO1996028144A1 (fr) * 1995-03-13 1996-09-19 The Procter & Gamble Company Emploi de ketorolac pour le traitement d'epithelioma spinocellulaires de la cavite buccale ou de l'arriere gorge
WO2000015195A1 (fr) 1998-09-10 2000-03-23 Nycomed Danmark A/S Compositions a base de substances medicamenteuses a usage pharmaceutique a liberation rapide
WO2004108110A1 (fr) 2003-06-10 2004-12-16 Silvestrini, Bruno Administration sublinguale de substances pharmacologiques anti-inflammatoires non steroidiennes
WO2006016125A1 (fr) * 2004-08-12 2006-02-16 Reckitt Benckiser Healthcare (Uk) Limited Granules composes de « a ains » et d’un polyol fabrique par extrusion de matiere fondue
US20060128782A1 (en) * 2003-06-02 2006-06-15 Guido Vandoni Pharmaceutical composition based on ketorolac or one of its salts pharmaceutically acceptable and use of ketorolac or its salts in pharmaceutical compositions
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
WO2009087658A2 (fr) 2007-11-07 2009-07-16 Sun Pharma Advanced Research Company Limited Composition appropriée pour une administration parentérale
WO2012127497A1 (fr) 2011-03-04 2012-09-27 Cadila Healthcare Limited Compositions pharmaceutiques stables de kétorolac ou des sels de celui-ci
EP3028698A1 (fr) * 2013-08-02 2016-06-08 Laboratorio Raam de Sahuayo, S.a. de C.V. Système à libération modifiée en trois phases d'un anti-inflammatoire non stéroïdien
WO2016151461A1 (fr) * 2015-03-24 2016-09-29 Nu Therapeutics Private Limited Film sublingual de kétorolac

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
RU2509560C1 (ru) * 2013-03-22 2014-03-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые терапевтические комбинации миртазапина для применения при болевых расстройствах

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
WO1996028144A1 (fr) * 1995-03-13 1996-09-19 The Procter & Gamble Company Emploi de ketorolac pour le traitement d'epithelioma spinocellulaires de la cavite buccale ou de l'arriere gorge
WO2000015195A1 (fr) 1998-09-10 2000-03-23 Nycomed Danmark A/S Compositions a base de substances medicamenteuses a usage pharmaceutique a liberation rapide
US20060128782A1 (en) * 2003-06-02 2006-06-15 Guido Vandoni Pharmaceutical composition based on ketorolac or one of its salts pharmaceutically acceptable and use of ketorolac or its salts in pharmaceutical compositions
US7879901B2 (en) 2003-06-02 2011-02-01 Nature's Plus Farmaceutica Ltda. Sublingual Formulations of Ketorolac or Salts Thereof
WO2004108110A1 (fr) 2003-06-10 2004-12-16 Silvestrini, Bruno Administration sublinguale de substances pharmacologiques anti-inflammatoires non steroidiennes
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
WO2006016125A1 (fr) * 2004-08-12 2006-02-16 Reckitt Benckiser Healthcare (Uk) Limited Granules composes de « a ains » et d’un polyol fabrique par extrusion de matiere fondue
WO2009087658A2 (fr) 2007-11-07 2009-07-16 Sun Pharma Advanced Research Company Limited Composition appropriée pour une administration parentérale
WO2012127497A1 (fr) 2011-03-04 2012-09-27 Cadila Healthcare Limited Compositions pharmaceutiques stables de kétorolac ou des sels de celui-ci
EP3028698A1 (fr) * 2013-08-02 2016-06-08 Laboratorio Raam de Sahuayo, S.a. de C.V. Système à libération modifiée en trois phases d'un anti-inflammatoire non stéroïdien
WO2016151461A1 (fr) * 2015-03-24 2016-09-29 Nu Therapeutics Private Limited Film sublingual de kétorolac

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Excipients", 1986, AMERICAN PHARMACEUTICAL ASSOCIATION
MANDEMA ET AL., CLIN PHARMACOL THER, vol. 60, no. 6, 1996, pages 619 - 35

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024211978A1 (fr) * 2023-04-13 2024-10-17 Aché Laboratórios Farmacêuticos S.A. Composition pharmaceutique orale, procédé de production de granulés ou d'une composition pharmaceutique orale, granulé pharmaceutique oral, utilisation de la composition pharmaceutique et méthode de traitement d'états inflammatoires, de la douleur et/ou pour éviter l'utilisation d'opioïdes en péri-opératoire

Also Published As

Publication number Publication date
RU2677663C1 (ru) 2019-01-18
UA126916C2 (uk) 2023-02-22

Similar Documents

Publication Publication Date Title
JP6545839B2 (ja) 口腔内崩壊錠及びその製造方法
KR101342786B1 (ko) 솔리페나신 또는 그의 염의 안정한 입자상 의약 조성물
RU2271805C2 (ru) Препарат, содержащий натеглинид
EP1218889B1 (fr) Compositions a liberation controlee contenant de la nimesulide
CN1913876B (zh) 含药物的颗粒和包含这种颗粒的固体制剂
KR100660072B1 (ko) 음식물 효과-비의존적으로 방출되는 다중 단위 제약 제제및 그의 제조 방법
KR101801424B1 (ko) 날부핀-기재 제제 및 그것의 용도
BRPI0714514B1 (pt) Grânulo compreendendo núcleo revestido por oxicodona, bem como comprimido para desintegração oral e seu processo de fabricação
BG64368B1 (bg) Фармацевтични състави на итраконазол
BR112012028035B1 (pt) formulação de liberação imediata
KR20100119539A (ko) 다이펜하이드라민을 포함하는 경구 분해성 정제
US20120276199A1 (en) Taste masked pharmaceutical formulations
US10842759B2 (en) Pharmaceutical compositions for N-propargylamine derivative
CA2845443A1 (fr) Comprime de nabilone se desintegrant en bouche et methode de fabrication associee
TW200914051A (en) Extrudates with improved taste masking
JP2023502209A (ja) アピキサバンの口腔内崩壊性医薬組成物
KR102239291B1 (ko) 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
JPWO2008114859A1 (ja) ピラゾール誘導体を含有する医薬組成物
WO2018197932A1 (fr) Compositions pharmaceutiques de kétorolac
KR102568681B1 (ko) 네포팜을 포함하는 경구 붕해 약학 조성물 및 그 제조 방법
JP2008506679A (ja) 抗ヒスタミン組成物
KR102090135B1 (ko) 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 포함하는 구강 붕해정 및 이의 제조방법
WO2024095137A1 (fr) Composition pharmaceutique d'empagliflozine et procédé associé
WO2023067620A1 (fr) Compositions pharmaceutiques de rivaroxaban à désintégration orale
US20160058730A1 (en) Pharmaceutical compositions of teriflunomide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17754788

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17754788

Country of ref document: EP

Kind code of ref document: A1